Range of suitable people: CDEC talked over the uncertainty in the volume of people with reasonably critical to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who will be categorised as acquiring gentle or m